Most Read Articles
Tristan Manalac, 09 Sep 2018
Structured and remote patient management interventions are effective in reducing all-cause mortality and the number of days lost due to unplanned hospitalizations in heart failure patients, according to a recent study.
Radha Chitale, 08 Apr 2016
A trial assessing the implantable CardioFit® device designed to stimulate the parasympathetic nervous system in heart failure patients failed to meet its primary endpoints – reducing the rate of hospitalization due to heart failure or death by any cause.
27 Aug 2018
Obese men appear to have better ST-elevation myocardial infarction (STEMI) prognoses than their normal weight counterparts, regardless of metabolic syndrome status, a recent study has shown.
Stephen Padilla, 04 Sep 2018
The prevalence of individuals with hypertension is expected to rise significantly with the implementation of the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) high blood pressure guidelines, according to a study.

Beyond angina relief – Optimizing management of CAD with VASTAREL® MR®

08 Nov 2017
Available in Europe since 1978, trimetazidine was launched in Malaysia in 1986 as VASTAREL® 20, with the first box of this medication sold in 1987. At that time, this agent was available as three times daily dosing; this was soon followed by the modified-release formulation, ie, VASTAREL® MR®, launched in 2005 to simplify the dosing regimen. By 2007, VASTAREL® MR® had become widely available in public hospitals throughout Malaysia.The efficacy of trimetazidine in coronary artery disease (CAD) is well established – it is a well-tolerated anti-ischaemic agent with no effect on blood pressure or heart rate. It is also recommended by Malaysian and international guidelines for symptomatic relief of angina. In conjunction with the 30th anniversary of VASTAREL®, renowned local and international opinion leaders gathered at a Servier symposium, chaired by Dr Jeyamalar Rajadurai, to reflect on the evolution of CAD management and the contemporary role of trimetazidine.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 09 Sep 2018
Structured and remote patient management interventions are effective in reducing all-cause mortality and the number of days lost due to unplanned hospitalizations in heart failure patients, according to a recent study.
Radha Chitale, 08 Apr 2016
A trial assessing the implantable CardioFit® device designed to stimulate the parasympathetic nervous system in heart failure patients failed to meet its primary endpoints – reducing the rate of hospitalization due to heart failure or death by any cause.
27 Aug 2018
Obese men appear to have better ST-elevation myocardial infarction (STEMI) prognoses than their normal weight counterparts, regardless of metabolic syndrome status, a recent study has shown.
Stephen Padilla, 04 Sep 2018
The prevalence of individuals with hypertension is expected to rise significantly with the implementation of the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) high blood pressure guidelines, according to a study.